{"contentid": 488127, "importid": NaN, "name": "FDA snubs Novo Nordisk\u00e2\u0080\u0099s once-weekly semaglutide", "introduction": "Novo Nordisk late Monday announced that the US Food and Drug Administration has issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0mg for the treatment of type 2 diabetes, which was filed on 20 January 2021.", "content": "<p>Novo Nordisk (NOV: N) late Monday announced that the US Food and Drug Administration has issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0mg for the treatment of type 2 diabetes, which was filed on 20 January 2021.</p>\n<p>A refusal to file letter is received when the FDA determines additional information is required to review a complete application. The news saw the Daish diabetes care giant&rsquo;s shares dip 2.3% to 433.10 kroner by late afternoon today.</p>\n<p>In the letter, the FDA has requested additional information including data relating to a proposed new manufacturing site. While additional information needs to be included in the resubmission, Novo Nordisk believes the already completed clinical trial program will be sufficient for approval of the label expansion application.</p>\n<h2><strong>May be part of FDA inspection backlog</strong></h2>\n<p>Although Novo Nordisk did not mention this in its announcement, during the COVID-19 pandemic the FDA has built up a significant backlog of manufacturing site inspections that has led to delays of approval decisions for dozens of drug candidates&nbsp;</p>\n<p>Novo Nordisk expects to resubmit the application to FDA during the second quarter of 2021.</p>\n<p>The FDA first approved oral semaglutide under the trade name Rybelsus in September 2019, making it the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the USA that does not need to be injected.</p>\n<p>Full-year 2020 Rybelsus sales were 1,837 million kroner ($296 million), versus 50 million kroner in 2019. While most see the potential for at least $2 billion in annual sales, Johan Unnerus, an analyst at Pareto Securities, has forecast 2026 revenues for Rybelsus in excess of $5 billion.</p>", "date": "2021-03-23 14:17:00", "meta_title": "FDA snubs Novo Nordisk\u00e2\u0080\u0099s once-weekly semaglutide", "meta_keywords": "Novo Nordisk, Rybelsus, Once-weekly, Semaglutide, Refuse to file, FDA, Oral", "meta_description": "FDA snubs Novo Nordisk\u00e2\u0080\u0099s once-weekly semaglutide", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-23 14:16:35", "updated": "2021-03-23 14:23:54", "access": NaN, "url": "https://www.thepharmaletter.com/article/fda-snubs-novo-nordisk-s-once-weekly-semaglutide", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "novo_nordisk_2021_night.jpg", "image2id": "novo_nordisk_2021_night_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Diabetes", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "Denmark, USA", "company_tag": "Novo Nordisk", "drug_tag": "Rybelsus, semaglutide", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-23 14:17:00"}